Delivery Order SPE2DR25D3103-SPE2DR26F9M42
Award Date 12/5/25
Potential Completion Date 12/8/25
Potential Value $48K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $1,830.91 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on November 13, 2025, with completion by November 14, 2025. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Ruxience 500 mg/50 ml vials, a biosimilar medication used in cancer treatment and other therapeutic applications. This $5,073.74 firm fixed-price delivery order, with a completion date of November 5, 2025, represents a routine pharmaceutical procurement executed under a competitive, non-set-aside process. The award is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,818.09 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer and immunological disorder treatment. This firm fixed price delivery order was issued on October 30, 2025, with an ultimate completion date of October 31, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,092.68 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of December 5, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion comprehensive pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $25,262.82 delivery order for Ruxience 500 mg/50 mL vials on September 25, 2025, with completion targeted for September 26, 2025. This firm fixed-price contract represents a non-competed award under an existing vehicle and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in the treatment of various cancers and autoimmune conditions, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ruxience 500 mg/50 ml vials, a biosimilar monoclonal antibody used in cancer and autoimmune disease treatment. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $4,892.20 and an ultimate completion date of August 15, 2025. The contract involves no set-aside designation and utilizes AmerisourceBergen's place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ruxience 500 mg/50 ml vials valued at $5,969.24 under a firm fixed-price contract type. Ruxience is a biosimilar to rituximab, used in treating various cancers and autoimmune conditions. The delivery order carries an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $4,950.90 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 ml vials on October 29, 2025, with completion expected by October 30, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,551.54 for Ruxience 500 mg/50 mL vials on November 25, 2025, with completion expected by November 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, representing the...